The following companies meet the definition of 'substantially affected organizations' (SAO) even though they are not identified as such on the Dun & Bradstreet (D&B) listing (see List of SAOs and description of how SAOs are identified).
If an IC Ethics Official identifies a questionable entity and suggests inclusion on the SAO list, send sufficient information about the entity, including rationale for why it should be considered an SAO, to your assigned NEO Specialist for a determination. Confirmed entities will be added to this list. If an entity has additional information available, the name is linked to the other information.
Format: Entity Name (Date added to list - Month/Year)
23andMe (ME) (12/21) | Lannett Co. Inc (LCI) (12/18) |
AbbVie (3/13) | Mahana Therapeutics (3/22) |
Acordia Therapeutics, Inc. (6/14) | Manhattan Scientifics Inc (MHTX) (03/17) |
Acceleron Pharma (11/18) | Medtronics (8/11) |
Affymetrix (11/06) | Merus Labs International (Norgine BV) (MSLI) (12/18) |
Allakos, Inc (11/18) | MilliporeSigma (formerly known as EMD Millipore) (7/19) |
Anacore Pharmaceuticals, Inc. (6/14) | Mind Medicine, Inc. (MNMD) (4/22) |
Anavo Therapeutics (11/23) | Mindray Medical International Ltd (7/09) |
Applied DNA Sciences (APDN) (12/21) | MST Medical Surgery Technologies, Inc. (8/13) |
argenx SE (ARGX) (5/20) | Nano-X Imaging Ltd. (NNOX) (4/21) |
Aurinia Pharmaceutical Inc. (AUPH) (4/22) | Neogenomics, Inc. (NEO) (3/20) |
Avita Medical Limited (2/20) | NOVENESIS (10/24) |
Baxalta, Inc (Shire Plc) (12/18) | NovoCure Limited (NVCR) (6/21) |
Bayer Aktiengesellschaft (8/19) | ObsEva SA (OBSV) (4/20) |
BioLineRx (BLRX) (4/21) | Oncology Pharma, Inc. (ONPH) (3/22) |
Bio-Rad Laboratories (8/06) | Pacific Biosciences (4/13) |
Bio-Reference Laboratories (3/08) | PainReform Ltd. (11/22) |
Bionano Genomics, Inc. (BNGO) (4/21) | PharmEnable (8//22) |
BioNTech (BNTX) (11/21) | Photovac (4/06) |
Braxia Scientific Corp. (BRAXF) (1/24) | Portilla Pharmaceuticals (6/14) |
Capstan Therapeutics (4/23) | Prana Biotechnology (3/12) |
Cardinal Health (CAH) (5/16) | Procter & Gamble Company (P&G) (7/19) |
Check Cap LTD (CHEK) | Propanc Biopharm, Inc. (PPCH) (11/18) |
China Medical Technologies (2/10) | ProQR Therapeutics N.V. (2/15) |
Clovis Oncology (4/23) | Qiagen (8/08) |
CRISPR Therapeutics (CRSP) (4/21) | QLT Inc, Vancouver, Canada (5/10) |
Darwin Biosciences (11/24) | ReceptoPharm (12/18) |
DNAPrint Genomics, Inc. (5/11) | Relief Therapeutics Holding SA (RLFTF) (4/21) |
Elysium Therapeutics, Inc. (6/13) | Sagent Pharmaceuticals, Inc. (5/14) |
EssilorLuxottica (ESLOY) (8/21) | Seagen, Inc. (SGEN) (6/21) |
FlexBioTech (3/23) | Shenzhen Mindray Biomedical Electronics (7/09) |
FSD Pharma Inc. (HUGE) (4/23) | Smith & Nephew (8/10) |
Galena (GALE) Biopharma, Inc. (7/13) | Surgivision (4/06) |
GeneDx (2/10) | Symmetry Medical (4/07) |
General Electric Capital (GEH) (11/18) | TaiMed Biologics (12/18) |
General Electric HealthCare (GEHC) (2/23) | Taysha Gene Therapies (TSHA) (1/22) |
Generex Biotechnology Crop (5/11) | Techniplast, USA (10/07) |
Given Imaging (5/06) | Tekla Healthcare Opportunities (7/14) |
GW Pharmaceuticals (09/13) | Tekmira Pharmaceuticals (8/14) |
Healthpure, Inc. (05/17) | The Institute for In Vitro Sciences, Inc (7/22) |
Hospira (4/13) | The McConnell Group (10/07) |
Hypermarcas S.A. (3/15) | TomoTherapy (7/08) |
IQVIA - formerly Quintiles IMS Holdings Inc (IVQ) (12/18) | Transgenomic (2/12) |
Illumina Inc. (6/14) | Trinity Biotech (10/14) |
Immunotech Laboratories (IMBB) (12/18) | Unimicro Technologies (7/08) |
InMode (INMD) (11/21) | Viataris Inc. (VTRS) (4/21) |
Isarna Therapeutics (5/14) | VolitionRX (VNRX) (4/21) |
Kenvue (KVUE) (8/24) | West Pharmaceutical Services, Inc. (3/23) |
Kinetic Concepts, Inc. (6/09) | World Precision Instruments (10/07) |
Lab Products, Inc (10/07) | Wuxi Pharma Tech (4/14) |
Updated: 12/2/2024
SAO Links:
- Introduction
- General Guidance About SAOs
- Sector Funds
- List of Substantially Affected Organizations (SAOs)
- List of Non-SAOs
- North American Industrial Classification System (NAICS) Codes
For additional information, contact your IC's Deputy Ethics Counselor or Ethics Coordinator.